Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Sees Large Decline in Short Interest

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 106,500 shares, a decline of 43.4% from the January 31st total of 188,200 shares. Currently, 1.3% of the shares of the company are short sold. Based on an average daily volume of 2,240,000 shares, the short-interest ratio is presently 0.0 days.

Insider Buying and Selling at Cyclacel Pharmaceuticals

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of the business’s stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 23.97% of the company’s stock.

Cyclacel Pharmaceuticals Trading Down 10.1 %

Shares of NASDAQ:CYCC opened at $0.33 on Friday. The firm has a 50 day moving average of $0.36 and a 200-day moving average of $0.64. The stock has a market capitalization of $2.08 million, a PE ratio of -0.04 and a beta of 0.35. Cyclacel Pharmaceuticals has a 12 month low of $0.30 and a 12 month high of $4.00.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Cyclacel Pharmaceuticals in a report on Thursday. They issued a “sell” rating for the company.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.